Long-acting amylin analogues in weight research
Clinical research on cagrilintide reported dose-dependent reductions in body weight versus placebo in trial populations, attributed to amylin-receptor mediated satiety signalling and slowed gastric emptying. Its lipidated design extends half-life to support weekly dosing in study protocols.
In plain English
Cagrilintide mimics amylin, a pancreatic satiety hormone, and was engineered to last a week per dose. Published trial data exist but are specific to controlled pharmaceutical development programs.